469 related articles for article (PubMed ID: 34664206)
21. Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.
Kimoto E; Vourvahis M; Scialis RJ; Eng H; Rodrigues AD; Varma MVS
Drug Metab Dispos; 2019 May; 47(5):493-503. PubMed ID: 30862625
[TBL] [Abstract][Full Text] [Related]
22. Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects.
Mohamed MF; Coppola S; Feng T; Camp HS; Kim E; Othman AA
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1335-1344. PubMed ID: 34109764
[TBL] [Abstract][Full Text] [Related]
23. More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-Mediated Clearances.
Emami Riedmaier A; Burt H; Abduljalil K; Neuhoff S
J Clin Pharmacol; 2016 Jul; 56 Suppl 7(Suppl Suppl 7):S132-42. PubMed ID: 27385171
[TBL] [Abstract][Full Text] [Related]
24. Clinical assessment of momelotinib drug-drug interactions via CYP3A metabolism and transporters.
Ho YL; Gorycki P; Ferron-Brady G; Martin P; Vlasakakis G
Clin Transl Sci; 2024 Apr; 17(4):e13799. PubMed ID: 38634429
[TBL] [Abstract][Full Text] [Related]
25. Glycyrrhizin has a high likelihood to be a victim of drug-drug interactions mediated by hepatic organic anion-transporting polypeptide 1B1/1B3.
Dong J; Olaleye OE; Jiang R; Li J; Lu C; Du F; Xu F; Yang J; Wang F; Jia W; Li C
Br J Pharmacol; 2018 Sep; 175(17):3486-3503. PubMed ID: 29908072
[TBL] [Abstract][Full Text] [Related]
26. [Quantitative assessment of the risk of OATP1B1/1B3-mediated drug-drug interactions].
Mori D; Maeda K; Kusuhara H
Nihon Yakurigaku Zasshi; 2019; 154(4):210-216. PubMed ID: 31597901
[TBL] [Abstract][Full Text] [Related]
27. Mechanistic in vitro studies indicate that the clinical drug-drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3, NTCP and OAT3.
Elsby R; Coghlan H; Edgerton J; Hodgson D; Outteridge S; Atkinson H
Pharmacol Res Perspect; 2023 Apr; 11(2):e01060. PubMed ID: 36811234
[TBL] [Abstract][Full Text] [Related]
28. Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter Activity.
Huh Y; Plotka A; Wei H; Kaplan J; Raha N; Towner J; Purohit VS; Dowty ME; Wolk R; Vourvahis M; King-Ahmad A; Mathialagan S; West MA; Lazzaro S; Ryu S; Rodrigues AD
Pharm Res; 2023 Nov; 40(11):2639-2651. PubMed ID: 37561322
[TBL] [Abstract][Full Text] [Related]
29. Scutellarin is Highly Likely to be Responsible for Drug-Drug Interactions Mediated by Hepatic Organic Anion-Transporting Polypeptide1B3.
Liu J; Guo Y; Xu Y; Yuan L; Zhu H
Pharm Res; 2020 Oct; 37(12):232. PubMed ID: 33123800
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin.
Johnson M; Patel D; Matheny C; Ho M; Chen L; Ellens H
Drug Metab Dispos; 2017 Jan; 45(1):27-34. PubMed ID: 27737931
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the Selectivity of Several Organic Anion Transporting Polypeptide 1B Biomarkers Using Relative Activity Factor Method.
Chan GH; Houle R; Zhang J; Katwaru R; Li Y; Chu X
Drug Metab Dispos; 2023 Sep; 51(9):1089-1104. PubMed ID: 37137718
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
Custodio JM; Wang H; Hao J; Lepist EI; Ray AS; Andrews J; Ling KH; Cheng A; Kearney BP; Ramanathan S
J Clin Pharmacol; 2014 Jun; 54(6):649-56. PubMed ID: 24375014
[TBL] [Abstract][Full Text] [Related]
33. Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters.
Shoaf SE; Bricmont P; Repella Gordon J
Clin Transl Sci; 2021 Jul; 14(4):1535-1542. PubMed ID: 33742787
[TBL] [Abstract][Full Text] [Related]
34. The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins.
Hua WJ; Hua WX; Fang HJ
Cardiovasc Ther; 2012 Oct; 30(5):e234-41. PubMed ID: 21884024
[TBL] [Abstract][Full Text] [Related]
35. Results From Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3.
Heinig R; Fricke R; Wertz S; Nagelschmitz J; Loewen S
Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):803-815. PubMed ID: 36029368
[TBL] [Abstract][Full Text] [Related]
36. Mechanistic Static Model based Prediction of Transporter Substrate Drug-Drug Interactions Utilizing Atorvastatin and Rifampicin.
Mitra P; Kasliwala R; Iboki L; Madari S; Williams Z; Takahashi R; Taub ME
Pharm Res; 2023 Dec; 40(12):3025-3042. PubMed ID: 37821766
[TBL] [Abstract][Full Text] [Related]
37. A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin-integration of in vitro results, Phase I and Phase II data and model application for drug-drug interaction potential analysis.
Hanke N; Teifel M; Moj D; Wojtyniak JG; Britz H; Aicher B; Sindermann H; Ammer N; Lehr T
Cancer Chemother Pharmacol; 2018 Feb; 81(2):291-304. PubMed ID: 29204687
[TBL] [Abstract][Full Text] [Related]
38. Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interaction Potential of Vemurafenib Using R-Value and Physiologically-Based Pharmacokinetic Models.
Kayesh R; Farasyn T; Crowe A; Liu Q; Pahwa S; Alam K; Neuhoff S; Hatley O; Ding K; Yue W
J Pharm Sci; 2021 Jan; 110(1):314-324. PubMed ID: 32590030
[TBL] [Abstract][Full Text] [Related]
39. Examination of Physiologically-Based Pharmacokinetic Models of Rosuvastatin.
Bowman CM; Ma F; Mao J; Chen Y
CPT Pharmacometrics Syst Pharmacol; 2021 Jan; 10(1):5-17. PubMed ID: 33220025
[TBL] [Abstract][Full Text] [Related]
40. Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs).
Duan P; Zhao P; Zhang L
Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):689-705. PubMed ID: 27858342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]